Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (CODX) will participate in two global health events during UN General Assembly week in New York.
The company will attend a UNOPS-hosted partnerships reception on September 23, 2026, and join the September 25 side event “TB Today. Disease X Tomorrow. Let’s Prepare for the Next Respiratory Pandemic,” focused on tuberculosis and future respiratory threats. Co-Dx is advancing its molecular diagnostics platform, with clinical performance studies of the Co-Dx™ PCR MTB tuberculosis test underway in India via joint venture CoSara. In the United States, Co-Dx submitted a 510(k) and concurrent CLIA Waiver application in August 2026 for its Co-Dx™ PCR Flu A/B & RSV test on the Co-Dx PCR Pro® instrument. The platform has not yet been cleared or authorized and is not available for sale.
Co-Diagnostics (CODX)/b) announced that Chief Commercialization Officer Seth Egan will participate in a Global Health Technologies Coalition and Adjuvant Capital roundtable on September 22, 2026, in New York City.The discussion will focus on lessons from the ongoing Ebola outbreak, including systems, technologies and partnerships needed to improve outbreak response. The invitation follows Co-Dx’s work on diagnostic solutions for the current Bundibugyo virus outbreak in Africa. CoSara Diagnostics, the company’s joint venture, has advanced development of Bundibugyo virus and pan-Ebola tests for centralized laboratories and submitted its Bundibugyo test for third-party evaluation in India. Co-Dx also recently began a collaboration with ReadyGo Diagnostics to evaluate combining ReadyGo’s GoCollect sample-preparation technology with the Co-Dx PCR platform for decentralized, blood-based Ebola testing, although the Co-Dx PCR platform is not yet cleared or authorized by regulators or available for sale.
Co-Diagnostics (CODX) will participate in the joint WHO/Unitaid/UNAIDS Annual Consultation Meeting at WHO headquarters in Geneva, Switzerland, on September 17-18, 2026. Executive Vice President of Business Development Joseph Featherstone will represent the company at the gathering of diagnostic manufacturers, procurement and regulatory agencies, and other stakeholders focused on advancing equitable access to diagnostics.
WHO has issued guidance supporting near-point-of-care molecular diagnostics and tongue swab sampling to help close gaps in tuberculosis testing. The company states that its Co-Dx™ PCR MTB test is designed to meet this guidance, with clinical performance studies underway in India through its joint venture CoSara Diagnostics Pvt. Ltd. The broader Co-Dx PCR platform, including PCR Home®, PCR Pro®, a mobile app, and associated tests, has not been cleared or authorized by the FDA and is not yet available for sale.
Co-Diagnostics (CODX) and ReadyGo Diagnostics announced a collaboration to evaluate combining the Co-Dx PCR platform with ReadyGo’s GoCollect blood sample-preparation technology for point-of-need molecular testing, initially targeting decentralized Ebola virus detection and outbreak response.
The partners are conducting feasibility work to see if GoCollect-prepared capillary blood samples can be processed on the Co-Dx PCR platform as part of a streamlined, field-deployable workflow. Establishing blood as a compatible sample type could eventually enable testing for additional bloodborne pathogens such as HIV and hepatitis B and C, but compatibility, product development, and regulatory authorizations are still pending and commercial availability is uncertain.
Co-Diagnostics (CODX)/b) will host a press conference and live webcast on Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time.The event will take place at W New York – Times Square, 1567 Broadway, New York, NY 10036, with a concurrent webcast available to registered participants. Chief Executive Officer Dwight Egan will deliver a presentation followed by a question-and-answer session for media, analysts and investors.
Co-Diagnostics (CODX) has completed two new Vector Smart® mosquito surveillance laboratory installations in Florida, with installation and customer training underway for an additional laboratory in Indiana.
The new sites activate previously announced orders and expand a Vector Smart network that has served customers in 21 U.S. states, including 7 mosquito abatement districts in Florida. Rising dengue activity in Florida this season includes 73 locally acquired cases across five counties and 14 dengue-positive mosquito pools, underscoring demand for decentralized molecular surveillance. Vector Smart delivers rapid, local PCR data for mosquito-borne disease monitoring and is designed as a scalable, multi-test platform that can be applied to multiple pathogens as surveillance priorities change.
Co-Diagnostics (CODX) launched an integrated, localized cloud and mobile infrastructure in India on September 3, 2026 to support clinical studies of its point-of-care Mycobacterium tuberculosis (MTB) test and future deployment of the Co-Dx PCR platform*
The India-based cloud is designed for secure data management and compliance with local privacy and cybersecurity requirements. It enables mobile test analysis in decentralized, low-connectivity settings, syncing results when connections are restored. The company plans to replicate this architecture in Saudi Arabia and South Africa and to use aggregated, anonymized data for public health surveillance, AI-driven outbreak prediction and future data commercialization strategies, supported partly by Gates Foundation funding.
Co-Diagnostics (Nasdaq: CODX) announced the first international deployment of its Vector Smart® mosquito surveillance platform at an overseas United States Air Force base, including laboratory equipment, consumables and mosquito abatement reagents. This step follows domestic growth to 40 customers in 21 U.S. states and marks the product line’s first international expansion. Vector Smart multiplex PCR assays are designed to detect mosquito-borne pathogens such as West Nile virus, Eastern and Western equine encephalitis, St. Louis encephalitis, Zika, dengue and chikungunya, helping abatement districts improve situational awareness and the efficiency of control efforts.
Co-Diagnostics (Nasdaq: CODX)/b) reported that Chief Commercialization Officer Seth Egan participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable on August 13 in Salt Lake City, Utah. The 90-minute session, moderated by law firm Maschoff Brennen, gathered industry stakeholders to discuss innovation, AI’s impact on medical devices, data interoperability and commercialization strategies.Co-Diagnostics also highlighted its recent 510(k) premarket notification submission to the FDA for the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro platform. The point-of-care Co-Dx PCR platform, conceived during the pandemic, remains under FDA and other regulatory review and is not yet cleared or available for sale.
Co-Diagnostics (Nasdaq: CODX) reported second quarter 2026 revenue of $0.17 million, slightly above $0.16 million a year earlier, with a net loss of $6.3 million, or $1.46 per share, versus a $7.7 million loss, or $7.00 per share, in 2025.
Operating expenses declined to $6.3 million from $8.2 million, improving operating loss to $6.2 million. Adjusted EBITDA loss narrowed to $5.8 million from $7.2 million. Cash and cash equivalents were $3.6 million at June 30, 2026, down from $11.9 million at year-end 2025.
According to the company, it completed clinical and analytical studies and submitted an FDA 510(k) and CLIA waiver for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, advanced TB programs in India, secured Saudi manufacturing site approval, expanded a Mexico distribution agreement, and raised $3.0 million in a private placement.